Plus Therapeutics Inc (PSTV) concluded trading on Wednesday at a closing price of $0.32, with 3.78 million shares of worth about $1.21 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -71.58% during that period and on July 16, 2025 the price saw a gain of about 2.21%. Currently the company’s common shares owned by public are about 60.49M shares, out of which, 60.31M shares are available for trading.
Stock saw a price change of -8.16% in past 5 days and over the past one month there was a price change of 3.18%. Year-to-date (YTD), PSTV shares are showing a performance of -82.20% which decreased to -71.83% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.16 but also hit the highest price of $2.31 during that period. The average intraday trading volume for Plus Therapeutics Inc shares is 26.82 million. The stock is currently trading 7.84% above its 20-day simple moving average (SMA20), while that difference is down -11.26% for SMA50 and it goes to -65.89% lower than SMA200.
Plus Therapeutics Inc (NASDAQ: PSTV) currently have 60.49M outstanding shares and institutions hold larger chunk of about 2.64% of that.
The stock has a current market capitalization of $19.60M and its 3Y-monthly beta is at 0.64. It has posted earnings per share of -$2.50 in the same period. It has Quick Ratio of 0.99. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PSTV, volatility over the week remained 8.26% while standing at 17.07% over the month.
Stock’s fiscal year EPS is expected to rise by 66.32% while it is estimated to increase by 35.03% in next year. EPS is likely to grow at an annualized rate of 49.58% for next 5-years, compared to annual growth of 46.51% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by D. Boral Capital on March 17, 2025 offering a Buy rating for the stock and assigned a target price of $9 to it. Coverage by Ladenburg Thalmann stated Plus Therapeutics Inc (PSTV) stock as a Buy in their note to investors on January 25, 2021, suggesting a price target of $8 for the stock.
